Skip to main content
ROIV
NASDAQ Life Sciences

Roivant Sets $35,000 Price for LISRAYA and Launches 5 Weeks Early

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$34.86
Mkt Cap
$25.072B
52W Low
$11.85
52W High
$37.97
52W Position info
194% above low
Off High info
8.2% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $11.85.

Summary

Roivant priced LISRAYA at $35,000 per 30-count bottle and launched the drug commercially about five weeks ahead of schedule, adding commercial detail to yesterday's FDA approval.


Key Events · Product Development and Regulatory · ROIV

  • LISRAYA Priced at $35,000

    The first disclosed pricing for the newly approved dermatomyositis therapy sets the wholesale acquisition cost at $35,000 for a 30-count bottle of 30 mg tablets.

  • Commercial Launch 5 Weeks Early

    LISRAYA is commercially available as of August 28, 2026, ahead of prior guidance for a launch by end of September 2026. Prescribing is open, the specialty pharmacy network is live, and patient support is active.

  • First Targeted DM Therapy

    LISRAYA is the first targeted therapy, first once-daily oral therapy, and first TYK2/JAK1 inhibitor approved for dermatomyositis, with a broad label covering adults with any disease severity.

  • Multi-Indication Pipeline

    Three additional pivotal datasets are expected over the next 36 months: non-infectious uveitis topline data in 2H 2026, cutaneous sarcoidosis Phase 3 ongoing, and lichen planopilaris Phase 2b/3 initiated.


Analysis · ROIV · Life Sciences

Investors now have their first concrete look at the commercial economics of LISRAYA, the first-ever targeted therapy for dermatomyositis, after Roivant disclosed a wholesale acquisition cost of $35,000 per 30-count bottle and confirmed the drug is commercially available today — roughly five weeks ahead of its prior end-of-September launch guidance. The company estimates the U.S. market at roughly 70,000 adults. A multi-indication roadmap was also laid out, with three additional pivotal datasets expected over the next 36 months, starting with non-infectious uveitis topline data in the second half of 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $34.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.1B. The 52-week trading range was $11.85 to $37.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info